Product Pipeline

OUR MEDICINES IN DEVELOPMENT

Our priority is researching and developing medicines and vaccines that will benefit patients around the world. We are committed to addressing unmet needs across a number of important therapeutic areas including, Oncology, Inflammation & Immunology, Vaccines, Internal Medicine and Rare Disease, with the goal of delivering innovative products to patients.

Key Innovative Programs in Registration / Phase 3

Key Biosimilars Programs in Registration / Phase 3

Key Programs in Phase 2

Pipeline date and pdf

Pipeline Snapshot as of April 30, 2019

Download Complete Pipeline PDF

Discovery Projects
Phase 1

34
Phase 2

30
Phase 3

23
Registration

10
Total97

Compound Name	Indication	Phase	Submission Type	Compound Type
PF-06842433 Therapeutic Area: Vaccines Phase:Phase 2 Compound Type:Vaccine Business Segment: WRDM Mechanism of Action: Prophylactic Vaccine Go to clinical trial	Invasive and non-invasive Pneumococcal infections	Phase 2	New Molecular Entity	Vaccine
PF-06936308 Therapeutic Area: Vaccines Phase:Phase 1 Compound Type:Vaccine Business Segment: WRDM Mechanism of Action: Therapeutic Vaccine Go to clinical trial	Multiple Cancers	Phase 1	New Molecular Entity	Vaccine
PF-06928316 Therapeutic Area: Vaccines Phase:Phase 1 Compound Type:Vaccine Business Segment: WRDM Mechanism of Action: Prophylactic Vaccine Go to clinical trial	Respiratory Syncytial Virus Infection	Phase 1	New Molecular Entity	Vaccine
PF-06482077 Therapeutic Area: Vaccines Phase:Phase 3 Compound Type:Vaccine Business Segment: Biopharma Mechanism of Action: Prophylactic Vaccine Go to clinical trial	Invasive and non-invasive Pneumococcal infections (BREAKTHROUGH)	Phase 3	New Molecular Entity	Vaccine
PF-06760805 Therapeutic Area: Vaccines Phase:Phase 1 Compound Type:Vaccine Business Segment: WRDM Mechanism of Action: Prophylactic Vaccine Go to clinical trial	Invasive Group B streptococcus infection	Phase 1	New Molecular Entity	Vaccine
PF-06425090 Therapeutic Area: Vaccines Phase:Phase 3 Compound Type:Vaccine Business Segment: Biopharma Mechanism of Action: Prophylactic Vaccine Go to clinical trial	Primary clostridium difficile infection (FAST TRACK)	Phase 3	New Molecular Entity	Vaccine
PF-06886992 Therapeutic Area: Vaccines Phase:Phase 1 Compound Type:Vaccine Business Segment: WRDM Mechanism of Action: Prophylactic Vaccine Go to clinical trial	Serogroups ABCWY meningococcal infections	Phase 1	New Molecular Entity	Vaccine
PF-06753512 Therapeutic Area: Vaccines Phase:Phase 1 Compound Type:Vaccine Business Segment: WRDM Mechanism of Action: Therapeutic Vaccine Go to clinical trial	Prostate Cancer	Phase 1	New Molecular Entity	Vaccine
talazoparib (MDV3800) Therapeutic Area: Oncology Phase:Registration Compound Type:Small Molecule Business Segment: Biopharma Mechanism of Action: PARP inhibitor Go to clinical trial	Germline BRCA Mutated Metastatic Breast Cancer (E.U.)	Registration	New Molecular Entity	Small Molecule
PF-05280586, a potential biosimilar to Rituxan® /MabThera® (rituximab) Therapeutic Area: Oncology Phase:Registration Compound Type:Biosimilar Business Segment: Biopharma Mechanism of Action: CD20 Antigen Antagonist Go to clinical trial	Follicular Lymphoma (Biosimilar) (U.S.) / (E.U.)	Registration	Biosimilar	Biosimilar
Bavencio (avelumab) Therapeutic Area: Oncology Phase:Phase 3 Compound Type:Biologic Business Segment: Biopharma Mechanism of Action: Anti PD-L1 Go to clinical trial	Locally Advanced Squamous Cell Carcinoma of the Head and Neck (Biologic)	Phase 3	Product Enhancement	Biologic
Bavencio (avelumab) Therapeutic Area: Oncology Phase:Phase 3 Compound Type:Biologic Business Segment: Biopharma Mechanism of Action: Anti PD-L1 Go to clinical trial	1st Line Urothelial Cancer (Biologic)	Phase 3	Product Enhancement	Biologic
Bavencio (avelumab) Therapeutic Area: Oncology Phase:Phase 3 Compound Type:Biologic Business Segment: Biopharma Mechanism of Action: Anti PD-L1 Go to clinical trial	1st Line Gastric Cancer (Biologic)	Phase 3	Product Enhancement	Biologic
Bavencio (avelumab) Therapeutic Area: Oncology Phase:Phase 3 Compound Type:Biologic Business Segment: Biopharma Mechanism of Action: Anti PD-L1 Go to clinical trial	1st Line Non-Small Cell Lung Cancer (Biologic)	Phase 3	Product Enhancement	Biologic
Bavencio (avelumab) Therapeutic Area: Oncology Phase:Registration Compound Type:Biologic Business Segment: Biopharma Mechanism of Action: Anti PD-L1 Go to clinical trial	1st Line Renal Cell Carcinoma (Biologic) (Combo w/ Inlyta (axitinib)) (U.S.) / (E.U.) (BREAKTHROUGH - U.S.) Project advanced	Registration	Product Enhancement	Biologic
PF-06439535, a potential biosimilar to Avastin® (bevacizumab) Therapeutic Area: Oncology Phase:Registration Compound Type:Biosimilar Business Segment: Biopharma Mechanism of Action: VEGFR inhibitor Go to clinical trial	Non-Small Cell Lung Cancer (Biosimilar) (U.S.)	Registration	Biosimilar	Biosimilar
Xtandi (enzalutamide) Therapeutic Area: Oncology Phase:Phase 3 Compound Type:Small Molecule Business Segment: Biopharma Mechanism of Action: Androgen receptor inhibitor Go to clinical trial	Metastatic Hormone Sensitive Prostate Cancer	Phase 3	Product Enhancement	Small Molecule
Lorbrena (lorlatinib) Therapeutic Area: Oncology Phase:Phase 3 Compound Type:Small Molecule Business Segment: Biopharma Mechanism of Action: ALK Inhibitor Go to clinical trial	1st Line ALK Non-Small Cell Lung Cancer (ORPHAN - U.S.)	Phase 3	Product Enhancement	Small Molecule